海利爾(603639.SH):子公司製劑項目通過環保驗收
格隆匯5月22日丨海利爾(603639.SH)公佈,近日,青島奧迪斯生物科技有限公司收到“20,000噸農用化學品製劑及肥料製造項目(一期)竣工環境保護驗收意見”,該項目的環境保護設施按照環境影響報告表及審批部門審批決定建設並與主體工程同時投入使用,污染物排放滿足相應標準,實際建設中未發生重大變動,不存在《建設項目竣工環境保護驗收暫行辦法》第八條中的不予驗收通過情形,該項目符合建設項目環境保護竣工驗收條件,通過竣工環境保護驗收。
該項目符合公司戰略發展規劃,有利於進一步增強公司製劑產品供給能力,提升公司可持續發展能力和綜合盈利能力,將對公司未來經營產生積極影響。本次項目實施是目前公司主要產品產能的提升、規格品種的拓展延伸和生產力水平先進性保障,與現有產品產能具有互補性,能夠更加快速響應市場變化,更好的服務客戶需求。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.